Compare Global X Copper Miners ETF (COPX) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Copper Miners ETF vs BIO-TECHNE Corp — how do they compare? Global X Copper Miners ETF trades at $78.7, while BIO-TECHNE Corp trades at $71.23 (market cap $11.10B). The key difference: BIO-TECHNE Corp pays a 0.45% dividend while Global X Copper Miners ETF pays none, and BIO-TECHNE Corp is trading nearer its 52-week high, Global X Copper Miners ETF nearer its low. Which is the better fit depends on your goals.
| COPX | TECH | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $95.70 | $71.38 |
52-Week Low | $42.75 | $43.31 |
Market Cap | — | $11.10B |
Enterprise Value | — | $11.18B |
Dividend Yield | — | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
COPX (Global X Copper Miners ETF) trades at $74.35, down 2.86% amid bearish technical signals with all 16 moving average indicators signaling sell. The ETF provides exposure to copper mining companies benefiting from AI-driven electrification demand, though key financial ratios remain undisclosed in current data. Recent news highlights copper's structural role in AI infrastructure and energy transition.
Outlook hinges on copper supply-demand dynamics amplified by AI data center expansion, though technical weakness suggests near-term pressure. Risks include commodity price volatility and execution challenges in mining supply chains. Analyst sentiment remains constructive on long-term copper fundamentals despite current bearish technical positioning.
Bio-Techne (TECH) trades at $71.36, showing minimal daily movement (+0.08%) as the market digests Merck KGaA's $73 per share acquisition offer. The stock sits just 2.3% below the buyout price, with technical indicators showing bullish momentum. Fundamentally, the company maintains strong gross margins (64.96%) but faces declining net income margins (6.01% in 2025). Recent earnings show mixed results with one beat and two misses in the last four quarters.
The acquisition premium provides near-term upside potential, though shareholder litigation risks exist regarding deal fairness. Long-term investors face uncertainty about post-acquisition prospects, while current valuation metrics (P/E 101.94) appear stretched without the takeover scenario. The $73 offer price represents the primary catalyst, with downside risk to $50 if the deal fails.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X Copper Miners ETF
COPX tracks the Solactive Global Copper Miners Total Return Index, providing broad exposure to companies worldwide involved in copper mining, refining, and exploration. It serves as an equity-based alternative to copper futures, offering a leveraged play on copper demand driven by global infrastructure and the clean energy transition.
Read more on COPX →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
